Literature DB >> 7216433

Outcome of influenza infection: effect of site of initial infection and heterotypic immunity.

R A Yetter, S Lehrer, R Ramphal, P A Small.   

Abstract

An infection established throughout the total respiratory tract of mice with a highly lung adapted influenza virus (H0N1) led to death from viral pneumonia. The 50% lethal dose (LD(50)) was approximately the same as the 50% infectious dose (ID(50)). An infection with the same virus initiated in the nasal mucosa spread to the trachea and lungs over a 3- to 5-day period but was not lethal except at very high infecting doses. The LD(50) was 30,000 times the ID(50). Mice that had recovered from a prior infection with A/PC/73(H3N2) demonstrated enhanced recovery (heterotypic immunity) when challenged with A/PR/8/34(H0N1). Heterotypically immune mice infected while anesthetized with this potentially lethal virus stopped shedding virus from the nose, trachea, and lungs by day 7 and recovered. Heterotypically immune mice, infected awake, stopped shedding virus from the nose by day 5, and, in fact, the virus did not spread to the trachea or lungs. Thus, some of the variation in the severity of influenza infections may be explained by two factors: the site of initial infection and previous infection with heterotypic influenza virus.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7216433      PMCID: PMC551177          DOI: 10.1128/iai.29.2.654-662.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

2.  Infection of the upper respiratory tract of mice with influenza A virus.

Authors:  T IIDA; F B BANG
Journal:  Am J Hyg       Date:  1963-03

3.  Cytotoxic T cells in the lungs of mice infected with an influenza A virus.

Authors:  K L Yap; G L Ada
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

4.  Viral and mycoplasmal pneumonia in a prepaid medical care group during an eight-year period.

Authors:  H M Foy; M K Cooney; R McMahan; J T Grayston
Journal:  Am J Epidemiol       Date:  1973-02       Impact factor: 4.897

5.  Studies with avian influenza A viruses: cross protection experiments in chickens.

Authors:  W H Allan; C R Madeley; A P Kendal
Journal:  J Gen Virol       Date:  1971-08       Impact factor: 3.891

6.  Purification and properties of a progesterone-induced basic glycoprotein from the uterine fluids of pigs.

Authors:  T T Chen; F W Bazer; J J Cetorelli; W E Pollard; R M Roberts
Journal:  J Biol Chem       Date:  1973-12-25       Impact factor: 5.157

7.  Immunity to influenza in ferrets. VII. Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets to inactivated influenza virus vaccines.

Authors:  C McLaren; C W Potter
Journal:  J Hyg (Lond)       Date:  1974-02

8.  Heterotypic immunity to influenza in ferrets.

Authors:  R A Yetter; W H Barber; P A Small
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

9.  Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis.

Authors:  R Ramphal; R C Cogliano; J W Shands; P A Small
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

10.  INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

Authors:  J L SCHULMAN; E D KILBOURNE
Journal:  J Bacteriol       Date:  1965-01       Impact factor: 3.490

View more
  44 in total

1.  Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection.

Authors:  B S Bender; M P Johnson; P A Small
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

2.  Towards a quantitative understanding of the within-host dynamics of influenza A infections.

Authors:  Andreas Handel; Ira M Longini; Rustom Antia
Journal:  J R Soc Interface       Date:  2009-05-27       Impact factor: 4.118

3.  Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo.

Authors:  P M Taylor; B A Askonas
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

4.  Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.

Authors:  Paula A Lanthier; Gail E Huston; Amy Moquin; Sheri M Eaton; Frank M Szaba; Lawrence W Kummer; Micheal P Tighe; Jacob E Kohlmeier; Patrick J Blair; Michael Broderick; Stephen T Smiley; Laura Haynes
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

5.  Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice.

Authors:  H H Nguyen; F W van Ginkel; H L Vu; M J Novak; J R McGhee; J Mestecky
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection.

Authors:  Mark D Trottier; Douglas S Lyles; Carol Shoshkes Reiss
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

7.  The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.

Authors:  K F Hu; M Elvander; M Merza; L Akerblom; A Brandenburg; B Morein
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

Review 8.  Heterosubtypic immunity to influenza A virus: where do we stand?

Authors:  Kristie M Grebe; Jonathan W Yewdell; Jack R Bennink
Journal:  Microbes Infect       Date:  2008-07-09       Impact factor: 2.700

9.  A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.

Authors:  N L Davis; K W Brown; R E Johnston
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines.

Authors:  Libuse Janakova; Hilde Bakke; Inger Lise Haugen; Aud K H Berstad; E Arne Høiby; Ingeborg S Aaberge; Bjørn Haneberg
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.